MERCK KGAA

Merck KGaA’s AI partnership with Evinova and Bio‑Techne acquisition slash development time, cut costs, and expand its oncology, diagnostics, and biologics portfolio.

Merck KGaA unveils Europe‑wide share distribution to boost capital for oncology, neurodegenerative and autoimmune R&D, aligning with rising biopharma trends.

Merck KGaA unveils a €25 M, 2,000‑sqm BioReliance testing hub in Darmstadt to accelerate GMP‑compliant drug release and stability studies across Europe.

Merck KGaA’s $11.3 billion acquisition of Bio‑Techne expands its life‑science tools portfolio, boosts U.S. market presence, and fuels synergies for long‑term growth.

Merck KGaA’s $11.3 billion purchase of Bio‑Techne marks a bold pivot into life‑science tools, boosting diagnostics and therapeutics and expanding its global market footprint.

Merck KGaA’s 2026 outlook lifts, first‑quarter beats forecast, sparking an 8% surge to €131.65 and a 52‑week high, fueling investor confidence in its diversified portfolio.

Merck KGaA’s Q1 earnings on 13 May could spark a healthcare rally, as investors evaluate its oncology, neurodegenerative and EU‑driven drug strategy amid new EU funding rules.

Merck KGaA’s strategy: harnessing 5.1%‑CAGR sphingolipid growth and $20.3 b downstream processing to boost pharma innovation, resilience, and shareholder value amid volatile German markets.

Merck KGaA’s resilient healthcare pipeline, expanding lipid‑nanoparticle platform and dividend‑friendly policy drive medium‑term value amid market volatility.

Merck KGaA expands voting rights across Europe, boosting liquidity and shareholder engagement while reinforcing long‑term governance and value creation.